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Hypothalamic effects of 
progesterone on regulation of 
the pulsatile and surge release of 
luteinising hormone in female rats
Wen He1, Xiaofeng Li2, Daniel Adekunbi2, Yali Liu1, Hui Long1, Li Wang1, Qifeng Lyu1, Yanping 
Kuang1 & Kevin T. O’Byrne2
Progesterone can block the oestradiol-induced GnRH/LH surge and inhibit LH pulse frequency. Recent 
studies reported that progesterone prevented premature LH surges during ovarian hyperstimulation 
in women. As the most potent stimulator of GnRH/LH release, kisspeptin is believed to mediate the 
positive and negative feedback effects of oestradiol in the hypothalamic anteroventral periventricular 
(AVPV) and arcuate (ARC) nuclei, while the region-specific role of progesterone receptors in these 
nuclei remains unknown. This study examined the hypothesis that progesterone inhibits LH surge and 
pulsatile secretion via its receptor in the ARC and/or AVPV nuclei. Adult female rats received a single 
injection of pregnant mare serum gonadotropin followed by progesterone or vehicle. Progesterone 
administration resulted in a significant prolongation of the oestrous cycle and blockade of LH surge. 
However, microinjection of the progesterone receptor antagonist, RU486, into the AVPV reversed 
the prolonged cycle length and rescued the progesterone blockade LH surge, while RU486 into the 
ARC shortened LH pulse interval in the progesterone treated rats. These results demonstrated that 
progesterone’s inhibitory effect on the GnRH/LH surge and pulsatile secretion is mediated by its 
receptor in the kisspeptin enriched hypothalamic AVPV and ARC respectively, which are essential for 
progesterone regulation of oestrous cyclicity in rats.
The positive and negative feedback effects of oestradiol (E2) and progesterone are essential in regulating the cycli-
cal activity of the hypothalamic-pituitary-ovarian axis. Acting as a major inhibitory brake in the luteal phase of 
the ovarian/menstrual cycle, progesterone inhibits gonadotrophin-releasing hormone (GnRH) and luteinising 
hormone (LH) secretion1. Moreover, when administered before or concurrent with E2, progesterone inhibits E2 
positive feedback and abolishes the preovulatory GnRH and gonadotrophin surge. This blockade of the LH surge, 
observed in many species, including the rat2, ewe3, monkey4 and women5–7, is critical for synchronizing the wave 
of follicular development in the ovary and maintaining the length of luteal phase8, 9. Disturbances in progesterone 
inhibitory feedback have been implicated in infertility associated with enhanced GnRH/LH secretion10. Clinically, 
premature spontaneous LH surges are a major cause of cycle cancellation in women11 and recently, progesterone 
has been shown to successfully prevent premature LH surges in women undergoing ovarian stimulation, thereby 
validating its use in in vitro fertilization (IVF) regimes6, 7, 12. Despite its clinical and physiologic importance, the 
neural mechanisms underlying the inhibitory actions of progesterone on surge, and indeed pulsatile, release of 
GnRH/LH remain poorly understood.
Although progesterone regulates GnRH secretion via its hypothalamic receptors, the lack of progesterone 
receptors (PR) on GnRH neurones2 suggests its action may involve interneurons expressing sex steroid receptors. 
The most probable upstream afferents are kisspeptin expressing neurones, which are highly enriched with both 
oestradiol receptor (ER) and PR13, and project directly to the GnRH neurones14, 15. Additionally, knockout of PR 
in kisspeptin neurones in mice, results in loss of LH surges, irregular oestrous cycles and infertility16, 17.
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In rodent, there are two major populations of kisspeptin neurones: those in hypothalamic anteroventral 
periventricular nucleus (AVPV) which are thought to underlie the LH surge by mediating positive feedback effect 
of E2, and the arcuate kisspeptin population which coexpress neurokinin B and dynorphin (KNDy) and mediate 
steroid negative feedback actions on LH secretion18–20. In humans, KNDy neurones of the infundibular nucleus21 
(homologue to the ARC in other species) relay both steroid negative and positive feedback actions22. The KNDy 
neurones are strongly implicated in GnRH pulse generation. Neurokinin B and dynorphin are thought to stimu-
late and inhibit KNDy neurone activity respectively, driving episodic release of kisspeptin, which in turn drives 
pulses of GnRH release23. Interestingly, ARC kisspeptin neurones may also participate in the regulation of the 
LH surge. Ablation of KNDy neurones robustly increased the magnitude of the E2-induced LH surge in ovariec-
tomised rats24, which may be mediated by their projections to the AVPV kisspeptin neurones25 or directly to the 
GnRH neuronal cell bodies in the medial preoptic area (mPOA)26 and/or terminals in the median eminence25.
Since PR are expressed in virtually all KNDy neurones, they are thought to be critical in mediating proges-
terone feedback effects on GnRH and LH secretion. Studies in sheep have shown that dynorphin from KNDy 
neurones may meditate the action of progesterone on GnRH/LH pulsatile frequency27. However, the role of hypo-
thalamic PR in control of the LH surge is controversial. Previous studies have indicated that progesterone might 
act via its receptors in the mPOA to block the LH surge in rats28. In contrasts, the expression of PR on kisspeptin 
neurones is required for the LH surge and normal oestrous cyclicity in mice16, 17. Given the afore-mentioned, the 
role of AVPV and ARC PR in progesterone negative feedback effect on pulsatile LH secretion as well as the LH 
surge in the rodent remains unclear.
In the present study, we used bilateral microinjections of the potent PR antagonist, RU486, into the AVPV or 
ARC nuclei to investigate the inhibitory role of progesterone on the LH surge induced by pregnant mare serum 
gonadotropin (PMSG), which induces follicle development mimicking clinical ovarian stimulation and LH surge 
induction. Additionally, intra-nuclear administration of RU486 was used to examine the effects of progesterone 
on pulsatile release of LH and oestrous cyclicity in female Sprague-Dawley rats.
Results
Cannulae placement in the AVPV and ARC. The location of the intra-AVPV and intra-ARC cannulae 
were confirmed by microscopic histological inspection of cresyl‐violet stained brain sections. Only animals with 
appropriate bilateral cannulae placement in the AVPV or ARC were included in the analysis (Fig. 1). Of the 16 
rats that underwent hypothalamic cannulation, 13 and 12 were confirmed with correct bilateral cannulae in 
the AVPV or ARC, respectively. The remaining rats were excluded from the analysis due to inaccurate probe 
placement.
Effects of progesterone on ovarian cyclicity. To test whether exposure to progesterone influences ovar-
ian cyclicity, progesterone was administered on metestrus to normal cycling rats, as well as to pregnant mare 
serum gonadotropin (PMSG) primed rats to mimic an ovarian stimulation background as described in the 
method below. In the normal cycling rats, vaginal cytology reveals that the progesterone treatment prolongs 
cycle length (Progesterone vs Vehicle: 6.71 ± 0.67 vs 4.68 ± 0.35 d; n = 7 and 5, respectively; P < 0.05) (Fig. 2B), 
with a significant increase in time spent in metestrus but decrease in the diestrus phase (P < 0.05) (Fig. 2C). 
Representative examples of typical oestrous cyclicity in vehicle and progesterone treated animals and shown 
in Fig. 2A. Similarly, in PMSG-primed animals, progesterone administration lengthened the oestrous cycle 
(PMSG + Progesterone vs PMSG + Vehicle: 5.57 ± 0.81 vs 4.50 ± 0.71 d; n = 7 and 5, respectively; P < 0.05) 
(Fig. 2B), especially the metestrus phase (Fig. 2C). Of note, all vehicle injected PMSG-primed animals were 
proestrus on day 2 (day 0, PMSG treatment), whereas proestrus was delayed in the progesterone treated rats, and 
representative examples are illustrated in Fig. 2A.
Figure 1. Photomicrograph of the cannulae targeted sites in the hypothalamic anteroventral periventricular 
(AVPV) and the arcuate (ARC). Photomicrograph of cresyl-violet stained coronal section showing 
representative examples of bilateral cannula placement in the AVPV (A) and ARC (B) respectively. 
Magnification, ×1.25. The arrows indicate the site of cannula placement.
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Effects of progesterone on the LH surge in PMSG-primed rat. As expected from the proestrus smear, 
all vehicle injected PMSG-primed animals displayed a robust LH surge on the afternoon/evening of day 2 (day 0, 
PMSG treatment) (Fig. 3A,E and F). In contrast, none of the PMSG-primed females administered progesterone 
displayed an LH surge (Fig. 3B,E and F). Area under curve (AUC) analysis of the LH profile (12:00–20:00 h) on 
day 2 is shown in Fig. 3F.
Circulating progesterone levels were significantly elevated at 18:00 h on experimental day 0 post injection 
(124.62 ± 43.62 vs 22.79 ± 5.64 ng/ml vehicle control; P < 0.05) (Fig. 3C). Circulating levels of E2 measured on 
the afternoon of day 1, before the expected LH surge, as a measure of follicle development, did not differ between 
PMSG-primed female treated with vehicle or progesterone (224.1 ± 66.1 vs 254.2 ± 76.3 pg/ml, respectively; 
P > 0.05) (Fig. 3D).
Figure 2. Progesterone disrupted oestrous cyclicity in the female rats. (A) Representative profiles depicting 
oestrous cyclicity in female rats, as measured by vaginal cytology, before (days −8 to −1, baseline), during 
(day 0 to 1, treatment) and after (days 2 to 8, after-treatment) the two day period of treatment from metestrus 
with vehicle (oil; twice daily) only (Veh, top panel), progesterone (twice daily) only (Prog, second panel), single 
injection of PMSG (day 0 only) plus vehicle (twice daily) (PMSG + Veh) or single injection of PMSG (day 0 
only) plus progesterone (twice daily) (PMSG + Prog, bottom panel) in normal cycling rats. P, proestrus; E, 
oestrus; M, metestrus; D, diestrus. (B) Average oestrous cycle length of the treatment cycle per se. (C) Average 
time spent in each stage of the cycle of the treatment cycle per se. Data were analysed by two-way ANOVA. 
*P < 0.05, Veh vs Prog; n = 5–7 per group.
www.nature.com/scientificreports/
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Effects of progesterone receptor antagonism in the AVPV or ARC nuclei on LH surges and oes-
trous cyclicity in PMSG-treated rats. To determine whether progesterone signalling within the AVPV 
or ARC may play a role in its inhibitory feedback effects on the LH surge and oestrous cyclicity, the progesterone 
receptor antagonist, RU486, was micro-infused into these brain areas in progesterone treated PMSG-primed 
animals described above. Administration of RU486 into the AVPV rescued the PMSG stimulated LH surge on 
day 2 (day 0, PMSG treatment) in 5 out of 7 animals (Fig. 4C), while no LH surge was evident in controls (n = 6) 
(Fig. 4A and E). In contrast, intra-ARC administration of RU486 failed to rescue the PMSG stimulus LH surge 
on day 2 (P > 0.05; n = 6 per group) (Fig. 4B,D and E). A summary of these data with AUC analysis of LH levels 
is provided in Fig. 4E.
Figure 3. Progesterone disrupted the LH surge in PMSG-primed female rats. Representative examples 
illustrating levels of LH in oil vehicle (Veh, A) or progesterone (Prog, B) treated animals at the expected time 
of the PMSG-induced LH surge on the afternoon of day 2. (C) Mean serum progesterone measured at 18:00 h 
on day 0 (day 0, PMSG treatment) after injection with vehicle or progesterone in PMSG-primed female rats. 
(D) Mean serum oestradiol level measured at 18:00 h on day 1 (day 0, PMSG treatment) after injection with 
vehicle or progesterone in PMSG-primed female rats. (E) Significant difference in peak LH levels at the time 
of the expected LH surge between oil controls and progesterone treated PMSG-primed animals. Baseline LH 
level at noon (12AM) on day 2 showed no difference. (F) Area under curve (AUC) analysis of LH levels at the 
time of the expected LH surge (12:00–20:00 h, day 2) in PMSG-primed female rats treated with oil vehicle or 
progesterone revealed a significant deference; n = 6 rats/group. Values were analysed by two-way ANOVA with 
group (Veh vs Prog). Results are presented as means ± SEM. *P < 0.05, Veh vs Prog; n = 5–7 per group.
www.nature.com/scientificreports/
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To verify the effects of progesterone on oestrous cyclicity, daily vaginal cytology was examined. Compared 
with vehicle infusion, bilateral intra-AVPV administration of RU486 significantly decreased cycle length in the 
presence of progesterone (P < 0.05; n = 6–7 per group) (Fig. 5A,B and C). However, intra-ARC administration 
of RU486 showed only a tendency to reduce cycle length compared with vehicle (P > 0.05; n = 6 per group) 
(Fig. 5D,E and F).
RU486 restores LH pulse frequency in progesterone treated female rats. To investigate the site 
of the inhibitory action of progesterone on LH pulse frequency, RU486 was bilaterally infused into the AVPV 
or ARC. Intra-ARC administration of RU486 significantly reduced LH pulse interval compared with controls 
(P < 0.05; n = 6–7 per group) (Fig. 6B,D and F). In contrast, intra-AVPV administration of RU486 had no effect 
on LH pulse interval in the presence of progesterone (P > 0.05; n = 6 per group) (Fig. 6A,C and E). LH pulse 
amplitude was not affected in any treatment group (data not shown).
Figure 4. Micro-infusion of RU486 into the AVPV reversed the inhibitory effects of progesterone on the 
LH surge in PMSG-primed female rats. Representative LH surge on the afternoon of day 2 (day 0, PMSG 
treatment) in response to intra-AVPV RU486 infusion in a progesterone treated animal (C). Intra-AVPV 
infusion of vehicle (artificial cerebrospinal fluid/DMSO/ethylene glycol) failed to reverse the inhibitory effect of 
progesterone on the LH surge (A). Representative examples showing the absence of LH surges on the afternoon 
of day 2 following intra-ARC vehicle control (B) or RU486 (D) after progesterone priming. (E) AUC analysis of 
LH level on the afternoon of day 2 after intra-AVPV or intra-ARC administration with vehicle (Veh) or RU486 
in PMSG-treated animals. Results are presented as means ± SEM. *P < 0.05, Veh vs RU486; n = 6–7 per group.
www.nature.com/scientificreports/
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Discussion
The present study provides direct evidence of a role for PR in the hypothalamic AVPV and ARC nuclei in medi-
ating the inhibitory effects of progesterone on surge and pulsatile release of LH, and oestrous cyclicity in female 
rats. Intra-AVPV administration of the progesterone antagonist, RU486, attenuated the inhibitory effect of pro-
gesterone on LH surges in PMSG-primed female rats, while antagonism of PR in the ARC restored LH pulse 
frequency in progesterone-treated animals.
Previous studies have shown that an increase in circulatory level of progesterone between oestrous to 
metestrus is related to prolonged oestrous cycle length in rats29, 30. Nequin L. G. et al.30 reported that higher 
endogenous serum progesterone level (around 88.5 ng/ml) after ovulation resulted in longer cycle length in 
rats. In accordance with these data, we confirm that exogenous administration of progesterone (serum level 
124.62 ± 43.62 ng) on metestrus prolonged oestrous cycle lengths, particularly the time spent in metestrus stage. 
PMSG has previously been used to stimulate and synchronize follicular growth and ovulation, mimicking ovarian 
stimulation in women31, 32. In the present study, progesterone extended oestrous cycle length, regardless of the 
prevailing oestrogenic milieu stimulated by PMSG. Everett et al.29 reported cycle prolongation by progesterone 
was accompanied by delayed ovulation, suggesting an antagonistic role of progesterone on oestrogenic stimula-
tion of ovulation. Steroid feedback on LH surge20 and pulse19 generation are mediated by kisspeptin signalling in 
the AVPV and ARC respectively. Kisspeptin neurone specific ER knockout mice arrest between the oestrous and 
diestrus phases and are anovulatory33. Similarly, antagonism of GnRH signalling inhibits spontaneous ovulation 
and oestrous cyclicity34. These data suggest that cycle arrest in metestrus and diestrus is accompanied by inter-
ruption of E2 feedback via kisspeptin on GnRH/LH secretion which is essential for ovulation33. Indeed, moderate 
knockdown of kisspeptin signalling in the AVPV, results in extended cycle length, and increased the time spent 
in metestrus and/or oestrus20. Of note, the present study shows that progesterone antagonism within the AVPV 
reversed the prolonged oestrous cycle length induced by progesterone. Additionally, PR knockout in kisspeptin 
neurones in adult female mice shows abnormal cycle with persistent diestrus and consequently anovulatory16. 
Figure 5. Effects of RU486 micro-infusion into the AVPV or ARC on progesterone induced prolongation of 
oestrous cycle length in PMSG-primed female rats. RU486 or vehicle (Veh) was injected via the AVPV or ARC 
nuclear cannulae an hour before each progesterone injection in PMSG-primed rats. Representative examples 
illustrating the effects of intra-AVPV micro-infusion of vehicle (Prog-Veh, A) or RU486 (Prog-RU486, B) on 
oestrous cycle length. (C) Intra-AVPV administration of RU486 before progesterone significantly shortened 
oestrous cycle length compared with vehicle controls. Representative examples illustrating the effects of intra-
ARC micro-infusion of vehicle (Prog-Veh, D) or RU486 (Pro-RU486, E) on oestrous cycle length. (F) Oestrous 
cycle length was not significantly altered by intra-ARC RU486 infusion compared with vehicle controls. Results 
are presented as means ± SEM. *P < 0.05, Veh vs Prog, n = 6–7 per group.
www.nature.com/scientificreports/
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It therefore appears that progesterone may interrupt oestrogen-kisspeptin-GnRH signalling in the AVPV, thus 
affecting ovulation and reproductive cycles.
Progesterone can either facilitate or inhibit E2-induced LH surges, depending on their temporal relationship. 
When administered after E2 priming, progesterone augments and synchronizes the preovulatory LH surge35, 
whereas high levels of progesterone, as during luteal phase of oestrous/menstrual cycle, block the stimulatory 
effects of E2 on LH surges in rats2, sheep3, 36 and primates4, including human5. In the present study, our data are 
consistent with these previous findings and demonstrates the inhibitory effect of progesterone on the GnRH/LH 
surge under a high E2 milieu induced by PMSG in female rats. Of note, these results are in line with our observa-
tion of prolonged cycle after administration of progesterone to mimic the component of the luteal phase of the 
Figure 6. Micro-infusion of RU486 into the ARC, but not the AVPV, reversed the inhibitory effects of 
intraperitoneal injection of progesterone on LH pulse frequency in female rats. Representative examples 
illustrating the effects of intra-AVPV administration of vehicle (artificial cerebrospinal fluid/DMSO/ethylene 
glycol) (A) or RU486 (C) on LH pulses in progesterone treated animals. (E) LH pulse interval was not altered 
by intra-AVPV administration of RU486 and compared with vehicle. Representative LH profiles illustrating 
the effects of intra-ARC administration of vehicle (B) or RU486 (D) in progesterone treated animals. (F) Intra-
ARC RU486 infusion significantly decreased LH pulse interval compared with vehicle controls. Results are 
presented as means ± SEM. *P < 0.05, Prog-Veh vs Prog-RU486; n = 6–7 per group. LH pulses are indicated by 
the asterisk (*).
www.nature.com/scientificreports/
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human menstrual cycle. Indeed, the ability of progesterone to blockade the preovulatory LH surge is the basis of 
the progesterone primed ovarian stimulation regime widely adopted for infertility patient in IVF clinic. Either 
endogenous progesterone in the luteal phase6, 37 or exogenous progesterone in follicular phase7 is sufficient to 
block the LH surge without compromising oocyte competence for women during ovarian stimulation.
Previous studies have shown that progesterone inhibits E2–induced GnRH release38 and decreases GnRH 
output in response to electrical stimulation of the mPOA39. Although early studies pointed to the hypothalamic 
preoptic area as a possible site for mediating progesterone inhibition of the LH surge28, there are no PR expressed 
in mPOA GnRH neurones2. However, kisspeptin neurones are enriched with both PR and ER40, 41, and project 
directly to the mPOA GnRH neurones14, suggesting they are the target of progesterone. It is generally accepted 
that E2 acts via ER in the AVPV kisspeptin neurones to activate GnRH neurones resulting in the LH surge40. 
However, there is yet no direct evidence for the specific role of PR in the AVPV kisspeptin neurones in regulating 
the LH surge. In the present study, we confirm the blockade of LH surges by progesterone, and further provide 
evidence for the site specific role of PR in the AVPV in mediating the inhibitory effect of progesterone on LH 
surges, based on the observation that progesterone antagonism within the AVPV rescues LH surges blocked by 
progesterone. A role of PR in the ARC seems inhibitory because intra-ARC administration of RU486 failed to 
rescue the inhibitory effect of progesterone on the LH surge. These data are in keeping with the role of AVPV 
kisspeptin in mediating the E2-induced LH surge20. Additionally, PR knockout in kisspeptin neurones result in 
blockade of E2-induced LH surges and lose of oestrous cyclicity in mice16, 17. It therefore appears that progester-
one inhibits the pre-ovulatory LH surge by interrupting activation of the AVPV kisspeptin neurones to elicit the 
GnRH/LH surge. Paradoxically, the ability of E2 to induce the LH surge is dependent on the presence and activa-
tion of PR42. While E2 induces PR expression in the AVPV43, progesterone down regulates its own receptors44, 45  
and may counteract the induction of PR by E2. Blockade of the LH surge by progesterone may therefore result 
from PR in the AVPV, thereby attenuating the ability of E2 to induce the LH surge.
The present study indicates that the ARC is a crucial site for progesterone’s inhibitory effect on LH pulse 
frequency in keeping with the role of this region in LH pulses generation20. Intra-ARC injection of RU486 signif-
icantly increased LH pulse frequency in progesterone treated rats. This result supports the findings of Goodman 
et al.46, where local antagonism of PR in the ARC interfered with the action of progesterone in reducing LH pulse 
frequency in sheep. As a critical component of the GnRH pulse generator, the ARC KNDy neurones are highly 
enriched with PR13, and have direct projections to GnRH cell bodies26 and terminals25. It has been reported that 
dynorphin released by KNDy neurones inhibit pulsatile GnRH secretion and may mediate progesterone negative 
feedback particularly in ewe27, 47, and a similar mechanism may operate in the rodent. Given the inhibitory role 
of dynorphin on LH secretion, it is suggested that progesterone may be act on ARC KNDy neurones and through 
dynorphin release inhibits pulsatile GnRH and LH secretion.
In conclusion, these data provide evidence that the inhibitory effect of progesterone on preovulatory surge 
and pulsatile secretion of LH is mediated by its receptor in the kisspeptin enriched hypothalamic AVPV and ARC 
respectively, which are essential for progesterone regulation of ovarian cyclicity.
Methods
Animals and surgical procedures. Female Sprague-Dawley rats weighing 150–200 g, obtained from 
Charles-Rivers (Margate, UK), were housed individually under controlled temperature (22 ± 2 °C), light condi-
tions (12:12 h light/dark, with lights on at 07:00 h) and fed with standard laboratory chow and water ad libitum. 
All surgical procedures were carried out under ketamine (100 mg/kg i.p.; Pharmacia and Upjohn, Crawley, UK) 
and Rompun (10 mg/kg i.p.; Bayer, Leverkusen, Germany) anaesthesia. All procedures were conducted in accord-
ance with the British Home Office Animals Scientific Procedures Animals Act 1986 (Project Licence 70/6237) 
and all experimental protocols were approved by the Animal Welfare and Ethical Review Body at King’s College 
London.
Jugular vein cannulation. Animals were implanted with two custom-made cardiac catheters via the jugular 
veins to enable serial blood sampling for profiling of LH levels48. The catheters were exteriorised at the back of 
the head and enclosed within a 30-cm light-weight metal spring tether (Instec Laboratories, Boulder, CO, USA) 
secured to the slotted screw (Instec Laboratories) affixed to the surface of the skull using dental cement (Dental 
Filling Ltd., Swindon, UK). The distal end of the tether was attached to a fluid swivel (Instec Laboratories), which 
allowed the rat freedom to move around the enclosure. After surgery, all rats were housed individually and exper-
iments commenced about 3 days later.
Bilateral AVPV or ARC cannulae implantation. To assess the effect of the anti-progesterone, RU486, in 
the hypothalamic AVPV or ARC nuclei, animals were secured in a David Kopf stereotaxic frame and implanted 
with bilateral guide cannulae (33-gauge; Plastics One, Roanoke, VA, USA) targeted towards the AVPV or ARC for 
later microinjection of drug. The respective coordinates for the ARC and AVPV were 0.40 mm lateral, 0.00 mm 
posterior to bregma, 8.60 mm below the surface of the dura, and 0.50 mm lateral, 3.40 mm anterior to bregma, 
10.10 mm below the surface of the dura according to the rat brain atlas of Paxinos and Watson49. A stainless steel 
slotted screw (Instec Laboratories) was affixed to the surface of the skull posterior to the guide cannulae and 
both were secured using dental cement (Dental Filling). The guide cannulae were then fitted with obturators 
(Plastics One) to maintain patency. After a 7-day recovery period the rats were implanted with cardiac catheters 
as described above. Experimentation commenced after a further 3-day recovery from surgery.
Hormone treatment. Treatment with PMSG has been validated for induction of follicle development to 
mimic ovarian stimulation50, 51 and induction of the LH surge32, and facilitates study of mechanisms underly-
ing these key reproductive processes. To test the action of progesterone on the LH surge female rats receiving 
www.nature.com/scientificreports/
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a single injection of PMSG (150 IU/kg, i.p., Sigma-Aldrich, Poole, UK) on the morning of metestrus, which 
results in an LH surge approximately 55 h later31, 32, were administered progesterone (5 mg/kg, i.p., in peanut oil, 
Sigma-Aldrich) twice daily (at 09:00 and 17:00 h) for two consecutive days starting immediately after the PMSG 
injection. For controls, PMSG-primed rats were injected with vehicle (0.3 ml, peanut oil, i.p., Sigma-Aldrich).
As an additional control group, to evaluate the effect of progesterone per se in normal cycling rats, progester-
one or vehicle only was given twice daily for two days starting on metestrus as described above.
Effects of progesterone on oestrous cyclicity. Vaginal lavage was performed daily between 07:00 and 
08:00 h to detect the stages of the oestrous cycle; proestrus, oestrus, metestrus and diestrus. Rats that displayed 
at least two consecutive 4- to 5-day oestrous cycles, with positive classification for all 4-stages were used. After 
at least one control oestrous cycle, PMSG-primed (n = 12) and non-PMSG (n = 10) treated control rats were 
randomly assigned on the morning of metestrus to receive either progesterone (5 mg/kg) or oil vehicle (0.3 ml) 
injections twice daily for 2 days as described above. Oestrous cyclicity was monitored for a further 8–10 days. The 
oestrous cycle length was calculated as the number of days between successive occurrences of oestrus. The time 
spent in each cycle stage was calculated as the proportion of days classified in each cycle stage.
Effects of progesterone on the LH surge in PMSG-primed rats. On the morning of day 2 (day 0, 
PMSG treatment) at 11:00 h the PMSG-primed animals were attached via one of the two cardiac catheter to a 
computer-controlled automated blood sampling system, which allows for the intermittent withdrawal of 25-µl 
blood samples without disturbing the animals48. Once connected, animals were left undisturbed for 1 h before 
sampling commenced at 12:00 h, when samples were collected hourly for 8 h (till 20:00 h) for LH measurement. 
After removal of each 25-µl blood sample, an equal volume of heparinized saline (50 U/ml heparin sodium/
ml normal saline; CP Pharmaceuticals, Wrexham, UK) was automatically infused into the animal to maintain 
patency of the catheter and blood volume. Blood samples were frozen at −20 °C for later assay to determine LH 
concentrations. Blood samples (25-µl) were also collected at 18:00 h on day 0 and day 1 for LH measurement dur-
ing experiment. Additional blood samples (200 µl) were collected at 18:00 h on days 0 and 1 for progesterone and 
E2 measurement, respectively, thus confirming hormone injection and status of follicular development.
Effects of progesterone receptor antagonism in the AVPV or ARC nuclei on LH surges and oes-
trous cyclicity in PMSG treated rats. A separate group of animals implanted with guide cannulae in 
the AVPV (n = 16) or ARC (n = 16) nuclei and cardiac catheters were monitored for normal oestrous cyclicity 
and then treated with the identical PMSG and progesterone regime described above. To examine the role of 
AVPV and ARC nuclear PR in surge release of LH, rats received bilateral intra-AVPV or intra-ARC injections of 
the anti-progesterone, RU486 (4 ng in 0.8 μl; Sigma‐Aldrich) or vehicle (0.8 μl, 60% artificial cerebrospinal fluid 
(aCSF), 20% DMSO and 20% ethylene glycol; Sigma‐Aldrich) 1 h before each intraperitoneal injected of proges-
terone (i.p. at 08:00 and 16:00 h for 2 days starting on metestrus). Internal cannulae (Plastics One) with extension 
tubing, preloaded with RU486 or vehicle, were inserted into the guide cannulae and extended 1.0 mm beyond 
the tips to reach the AVPV or ARC nuclei. The distal end of the extension tubing was connected to a 5‐μl syringe 
(SGE Analytical Science, Milton Keynes, UK). The tubing was held outside the cage to allowing remote infusion 
without disturbing the animal. The RU486 or vehicle was micro-infused at a rate of 0.1 μl/min for 8 min and the 
internal cannulae were kept in the guide cannulae for a further 2 min to prevent backflow. This procedure was 
repeated for each of the 4 injections.
At 11:00 h on day 2 (day 0, PMSG treatment) the animals were attached via a cardiac catheter to the blood 
sampling system, and left undisturbed for 1 h before sampling commenced at 12:00 h. Samples were collected 
hourly for 8 h for LH measurement as described above.
Oestrous cyclicity was monitored in this experimental group by examining daily vaginal cytology.
Effects of microinjection of RU486 into the AVPV or ARC on LH pulse. On completion of the exper-
iments described above, the same animals were used to examine the role of AVPV and ARC nuclear PR in pulsa-
tile release of LH, after a washout period of about two weeks during which recovery of normal oestrous cyclicity 
was observed. At 08:00 h on morning of metestrus, rats were given bilateral intra-AVPV or intra-ARC injection 
of RU486 (4 ng in 0.8 μl: Sigma‐Aldrich) or vehicle (0.8 μl, 60% artificial cerebrospinal fluid (aCSF), 20% DMSO 
and 20% ethylene glycol; Sigma‐Aldrich) as described above. One hour later (09:00 h), rats received an intraperi-
toneal injection of progesterone (5 mg/kg), and automated blood sampling commenced, as previously described, 
3 h later (12:00 h) with collection of 25-μl blood every 5 min for 2 h for LH measurement. All the samples were 
frozen at −20 °C for later assay.
Brain collection and histological verification of cannulae position. After experimentation, 0.5 µl 
India ink was injected through internal cannulae inserted into the guide cannulae for the purpose of site ver-
ification. Animal were then killed by decapitation. The brains were removed and snap frozen on dry ice, and 
then stored at −80 °C followed by sectioning (30-µm) using a cryostat (Bright Instrument Co Ltd., Luton, UK). 
To evaluate the cannulae position, every fourth section throughout the AVPV or ARC region corresponding to 
bregma −0.60 to 0.80 mm and 2.80 to 3.60 mm49, respectively, was mounted and stained with cresyl violet. Slides 
were then viewed under a light microscope and images were taken using a digital camera (Zeiss, Oberkochen, 
Germany). Only data from animals with correct cannulae placement were analysed.
Measurement of plasma LH, oestradiol and progesterone concentration. A double-antibody 
radioimmunoassay (RIA) supplied by the National Institute of Diabetes and Digestive and Kidney Diseases 
(Bethesda, MD, USA) was used to determine LH concentration in the 25-μlwhole blood sample52. The reference 
preparation was rLH-RP-3. The sensitivity of the assay was 0.093 ng/ml. The intra-assay coefficient of variation 
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was 6.5% and the inter-assay coefficient of variation was 7.4%. The E2 and progesterone plasma samples (50 μl) 
were measured by using the EIA kit (Labor Diagnostika Nord, Germany) which use was verified in rat53.
Statistical analysis. The effect of progesterone and RU486 on LH surges was determined by analysing the 
area under the LH profile curve (AUC) using Sigma Plot 12.0 (Systat Software, Inc., Chicago, IL). Detection of LH 
pulses was established through the use of the algorithm ULTRA54. Two intraassay coefficients of variation of the 
assay were used as the reference threshold for the pulse detection. The effect of intra-AVPV and intra-ARC RU486 
microinjection on parameters of LH secretion was calculated by comparing the mean basal levels of LH, mean 
LH pulses interval, or mean amplitude of LH pulses, within the experimental period between the two groups. A 
Student’s t test was used to analyse baseline LH, E2 and progesterone levels. All other results were analysed by a 
one-way ANOVA. Data are presented as the mean ± SEM and P < 0.05 was considered statistically significant.
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